- Home
- RDHL vs QNRX Comparison
RDHL vs QNRX Comparison
Compare RDHL & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- QNRX
- Stock Information
- Founded
- RDHL 2009
- QNRX 2018
- Country
- RDHL Israel
- QNRX United States
- Employees
- RDHL N/A
- QNRX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- RDHL Health Care
- QNRX Health Care
- Exchange
- RDHL Nasdaq
- QNRX Nasdaq
- Market Cap
- RDHL 3.8M
- QNRX 3.3M
- IPO Year
- RDHL N/A
- QNRX N/A
- Fundamental
- Price
- RDHL $1.85
- QNRX $9.60
- Analyst Decision
- RDHL
- QNRX
- Analyst Count
- RDHL 0
- QNRX 0
- Target Price
- RDHL N/A
- QNRX N/A
- AVG Volume (30 Days)
- RDHL 18.5K
- QNRX 12.9K
- Earning Date
- RDHL 04-10-2025
- QNRX 08-07-2025
- Dividend Yield
- RDHL N/A
- QNRX N/A
- EPS Growth
- RDHL N/A
- QNRX N/A
- EPS
- RDHL N/A
- QNRX N/A
- Revenue
- RDHL $8,042,999.00
- QNRX N/A
- Revenue This Year
- RDHL $381.91
- QNRX N/A
- Revenue Next Year
- RDHL N/A
- QNRX N/A
- P/E Ratio
- RDHL N/A
- QNRX N/A
- Revenue Growth
- RDHL 23.17
- QNRX N/A
- 52 Week Low
- RDHL $1.71
- QNRX $5.01
- 52 Week High
- RDHL $20.28
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- RDHL 43.03
- QNRX 64.78
- Support Level
- RDHL $1.72
- QNRX $8.04
- Resistance Level
- RDHL $2.08
- QNRX $8.58
- Average True Range (ATR)
- RDHL 0.09
- QNRX 0.46
- MACD
- RDHL 0.01
- QNRX 0.04
- Stochastic Oscillator
- RDHL 27.78
- QNRX 98.57
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.